Cargando…
COVID-19-related vaccines and therapeutics Preliminary insights on related patenting activity during the pandemic.
| Autor principal: | |
|---|---|
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Geneva :
World Intellectual Property Organization,
2022.
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Intro
- _Hlk93048502
- Acknowledgements
- Key findings
- Introduction
- Background
- biology of COVID-19
- Overview of patenting activity related to COVID-19
- Patent filings during 2020-2021
- Filing and publication of COVID-19-related patent applications over time
- COVID-19-related vaccine and therapeutic patent applicant profiles
- Research collaboration and IP strategies related to technologies important to COVID-19 vaccines and therapeutics
- Disclosure of sequences within patent documents
- COVID-19 vaccines
- Background
- vaccine platforms
- Conventional vaccine platforms
- Novel vaccine platforms
- Patent and vaccine distribution by vaccine platform and published applicant location
- Speed of vaccine development
- COVID-19 vaccine patent landscape
- Core vaccine technologies, collaboration and licensing
- Analysis of WHO data on COVID-19 vaccines
- Timelines on key technologies for COVID-19 vaccine development
- Technologies relevant to mRNA vaccine
- Timeline details for adenovirus vaccine development
- Timeline details for vaccine adjuvant development
- COVID-19 therapeutics
- Background
- Analysis of COVID-19 therapeutics-related patent applications by substances type
- Top locations of patent applicants for COVID-19 therapeutics and their filing strategies
- Highlights of patent filings related to COVID-19 therapeutic development
- Patent filings related to development of small-molecule drugs for COVID-19
- Patent filings related to the development of biologics for COVID-19
- Patents related to antibodies for COVID-19 treatment
- Peptide and protein therapies
- Nucleic-acid-based therapies
- Aptamer-mediated therapy
- Cell-based therapies
- Other biologic-based therapies
- Analysis of COVID-19 therapeutics in clinical trials
- Analysis of COVID-19 therapeutics data in the Milken Institute and Regulatory Affairs Professionals Society (RAPS) tracker data
- Distribution of COVID-19 drug candidates across small molecules and biologics, repurposed drugs and de novo synthesized drugs
- Classification of COVID-19 drug candidates in clinical trials by molecular nature and function
- Feature summary of examples of anti-COVID-19 drug candidates in clinical trials
- Perspectives
- Annex
- Data sources and methods
- Tables of vaccine types and candidates currently in clinical trials
- Examples of partial, early disclosure observed at the Israeli, U.K. and Singapore patent offices
- Glossary
- References
- Further reading